Skip to main content
. Author manuscript; available in PMC: 2014 Sep 26.
Published in final edited form as: Sci Transl Med. 2014 Mar 26;6(229):229ra40. doi: 10.1126/scitranslmed.3007696

Fig. 3. Systemic responses in LAD-I patients.

Fig. 3

(A) The indicated cytokines/chemokines were measured in blood plasma from healthy control subjects and LAD-I patients using multiplex luminex assays. The inset shows the percentage of neutrophils in the peripheral blood of the two groups (each point represents an individual). Data are means ± SEM (n = 5 per group). *P < 0.05 and **P < 0.01; unpaired t test. (B) Flow cytometry after intracellular staining for IL-17A in PBMC, from healthy (left) or LAD-I (right) subjects, stimulated with PMA and ionomycin. The PBMC were gated on CD45+CD3+ cells and the plots are representative of four separate experiments with paired LAD-I versus healthy control comparisons.

HHS Vulnerability Disclosure